Cytidine, 2'-deoxy-2',2'-difluoro- cas no:95058-81-4
Synonyms: 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;Cytidine, 2-deoxy-2,2-difluoro-2-Deoxy-.beta.-D-2,2-difluorocytidine;Gemcitabine [USAN:BAN:INN];DDFC;LY 188011;LY188011 hydrochloride;Cytosine, 1-(2-deoxy-2,2-difluoro-beta-D-erythro-pentofuranosyl)-;Gemcitabine hydrochloride [USAN];LY188011;2-Deoxy-2,2-difluorocytidine monohydrochloride;Gemzar;2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-2,2-difluoro-D-erythro-pentofuranosyl)-;2'-Deoxy-2',2'-Difluorocytidine;2',2'-Difluorodeoxycytidine(Gemcitabine base);
NameCytidine, 2'-deoxy-2',2'-difluoro-
CAS95058-81-4
Synonyms4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;Cytidine, 2-deoxy-2,2-difluoro-2-Deoxy-.beta.-D-2,2-difluorocytidine;Gemcitabine [USAN:BAN:INN];DDFC;LY 188011;LY188011 hydrochloride;Cytosine, 1-(2-deoxy-2,2-difluoro-beta-D-erythro-pentofuranosyl)-;Gemcitabine hydrochloride [USAN];LY188011;2-Deoxy-2,2-difluorocytidine monohydrochloride;Gemzar;2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-2,2-difluoro-D-erythro-pentofuranosyl)-;2'-Deoxy-2',2'-Difluorocytidine;2',2'-Difluorodeoxycytidine(Gemcitabine base);
Molecular FormulaC9H11F2N3O4
Molecular Weight263.2
Appearancewhite powder
refractive index1.652
Hazard Xn: Harmful;Xi: Irritant;
Risk R21
Safety
Hazard Codes:?
Xn,?
Xi
Risk Statements: 21-36/38-46-62-63?
R21:Harmful in contact with skin.?
R36/38:Irritating to eyes and skin.?
R46:May cause heritable genetic damage.?
R62:Risk of impaired fertility.?
R63:Possible risk of harm to the unborn child.
Safety Statements: 25-26-36/37-53?
S25:Avoid contact with eyes.?
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.?
S36/37:Wear suitable protective clothing and gloves.?
S53:Avoid exposure - obtain special instructions before use.
Human systemic effects When heated to decomposition it emits toxic vapors of NOx and F?.
1. |
??? |
ivn-man TDLo:27?mg/kg:PUL
|
??? |
JCROD7 ?? Journal of Cancer Research and Clinical Oncology. 125 (1999),637. |